

Trial ID	Lægemiddelstyrelse godkendelse	Videnskabetisk godkendelse	Status	Forsøgslægemidler	Betegnelse	Forsøgstitel	Sponsor	Koordinerende hospital i DK	Trial sites i DK	Indikation
2020-001052-18	22. marts 2020	25. marts 2020	Godkendt	Remdesivir, placebo	INSIGHT	A Multicenter, Adaptive, Randomised Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults - Version for European Union/United Kingdom Sites	Regents of the University of Minnesota, US	Rigshospitalet	9 afdelinger	Behandling af COVID-19 hos hospitaliserede voksne
2020-001154-22	27. marts 2020	06. april 2020	Godkendt	Tocilizumab, Placebo	WA42380 /Version 1	A randomized, double-blind, placebocontrolled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia	Roche	Hvidovre Hospital	4 afdelinger	Hospitaliserede patienter med alvorlig COVID-19 pneumoni
2020-001172-15	26. marts 2020	03. april 2020	Godkendt	APN01 (kendt som GSK2586881)	APN01-01-COVID19	Recombinant human angiotensin-converting enzyme 2 (rhACE2) as a treatment for patients with COVID-19	APEIRON Respiratory Therapies GmbH	Rigshospitalet	2 afdelinger	Behandling af patienter med COVID-19
2020-001198-55	24. marts 2020	03. april 2020	Godkendt	Hydroxychloroquin, azithromycin, placebo	ProBe-COVID-Trial	Pro-aktiv Beskyttelse af Indlagte Patienter med COVID-19	Jens-Ulrik Stæhr Jensen, Gentofte Hospital	Gentofte Hospital	7 afdelinger	Pro-aktiv Beskyttelse af Indlagte Patienter med COVID-19
2020-001200-42	27. marts 2020	30. marts 2020	Godkendt	Camostat mesilate	CamaCO-19-001	The Impact of Camostat Mesilate on COVID-19 Infection: An investigator-initiated randomized, placebo-controlled, phase IIa trial	Lars Østergaard, inf.sygdomme, Aarhus Universitetshospital	Aarhus Universitetshospital	9 afdelinger	Effekt på varigheden og sværhedsgraden af COVID 19
2020-001257-51	27. marts 2020	15. april 2020	Godkendt	Hydroxychloroquine	Pre-HCQ Dialysis Study	The Danish Pre-HCQ Dialysis Study: Hydroxychloroquine for prevention of COVID19 in dialysis-treated patients with end-stage renal disease - A multicenter parallel-group open randomized clinical trial	Nicholas Carlson, Rigshospitalet	Rigshospitalet	3 afdelinger	Forebyggelse af COVID19 i dialyse-behandlede patienter
2020-001275-32	27. marts 2020	03. april 2020	Godkendt	Tocilizumab, Sarilumab	APPI2-CV-2020-01	Effectiveness of Interleukin-6 Receptor Inhibitors in the Management of Patients with Severe SARS-CoV-2 Pneumonia: An Open-Label Multicenter Sequential Randomized Controlled Trial	The Parker Institute, DK	Bispebjerg Hospital	1 afdeling	COVID-19 patienter med alvorlig forværring i vejtrækningen
2020-001270-29	03. april 2020	07. april 2020	Godkendt	Hydroxychloroquine	EFC16858	An adaptive Phase 2/3, randomized, open-label study assessing efficacy and safety of hydroxychloroquine for hospitalized patients with moderate to severe COVID-19.	Sanofi	Hvidovre Hospital	1 afdeling	Indlagte patienter med moderat til svær COVID-19
2020-001395-15	06. april 2020	05. april 2020	Godkendt	Hydrokortison	COVID STEROID	Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia – the COVID STEROID Trial	Anders Perner, Rigshospitalet, intensiv afd.	Rigshospitalet	20 afdelinger	Patienter med COVID-19 og svær iltmangel (behov for højt ilttilskud eller respirator)
2020-001367-88	08. april 2020	14. april 2020	Godkendt	Hydroxychloroquine, baricitinib og sarilumab. Desuden convalescent plasma (ikke lægemiddel)	CCAP-RCT	Efficacy and safety of novel treatment options for adults with COVID-19 pneumonia. A double-blinded, randomized, multi-stage, 6-armed placebo-controlled trial in the framework of an adaptive trial platform	Thomas Benfield, Hvidovre Hospital	Hvidovre Hospital	12 afdelinger	Effekt og sikkerhed ved nye behandlingsmuligheder for voksne med COVID-19 pneumoni
2020-001420-34	11. april 2020	14. april 2020	Godkendt	Senicapoc	COVIPOC	Senicapoc in COVID-19 Patients with Severe Respiratory Insufficiency – A Randomized, Open-Label, Phase II Trial (COVIPOC).	Ulf Simonsen, Aarhus Universitet	Aarhus Universitetshospital	3 afdelinger	COVID-19 patienter med svær respiratorisk insufficiens
2020-001459-42	21. april 2020	17. april 2020	Godkendt	Ruxolitinib		Ruxolitinib i behandlingen af svær COVID-19 infektion. Et Dansk Effekt- og Sikkerhedsstudie.	Hans Hasselbalch	Sjællands Universitetshospital	1 afdeling	Nydiagnostiserede patienter med svær COVID-19 infektion, som kræver mekanisk ventilation (respiratorhjælp) eller patienter, som har et truende behov for respiratorstøtte.
2020-001363-85	17. april 2020	23. april 2020	Godkendt	Hydroxychloroquine		COVID-19 Prophylaxis with hydroxychloroquine, vitamin D, and zinc supplementation in Danish nursing home residents – a randomized controlled trial	Jesper Ryg, Odense Universitetshospital	Odense Universitetshospital	1 afdeling	Forebyggelse af Coronavirus hos plejehjemsboere
2020-001544-26	22. april 2020	17. april 2020	Godkendt	ACE-hæmmere (captopril, enalapril, lisinopril, perindopril, ramipril, trandolapril) og angiotensin II receptor hæmmere (candesartancilexetil, irbesartan, losartan, telmisartan, olmesartan-medoxomil, valsartan)	RASCOVID-19	Effects of discontinuing renin-angiotensin system inhibitors in patients with COVID-19 (RASCOVID-19)	Filip Krag Knop, Gentofte Hospital	Gentofte Hospital	2 afdelinger	ACE-hæmmere og angiotensin-II-receptorantagonisters påvirkning af COVID-19 forløb

Trial ID	Lægemiddelstyrelse godkendelse	Videnskabetisk godkendelse	Status	Forsøgslægemidler	Betegnelse	Forsøgstitel	Sponsor	Koordinerende hospital i DK	Trial sites i DK	Indikation
2020-001888-90	27. april 2020	30. april 2020	Godkendt	BCG vaccine, placebo		Using BCG vaccine to enhance nonspecific protection of health care workers during the COVID-19 pandemic. A randomised controlled multi-center trial	Christine Stabell Benn, Odense Hospital.	Odense Universitetshospital	7 afdelinger	Forbyggende for sundhedspersonale i kontakt med COVID patienter.
2020-001296-33	29. april 2020	06. maj 2020	Godkendt	Ilomedin (iloprost)	COMBAT-COVID-19	Effekt og sikkerhed af 72 timers infusion af Iloprost (1 ng/kg/min) til patienter med COVID-19 induceret respiratorisk endotheliopati – et multi-center, randomiseret, placebo kontrolleret, dobbelt-blindet investigator initieret klinisk forsøg.	Pär Ingemar Johansson, Københavns Universitetshospital	Rigshospitalet	5 afdelinger	Respiratorindlagte COVID-19 patienter.

6. maj 2020